ArticleBMC microbiology2026
The colonization rate and associated factors of vancomycin-resistant enterococci among HIV infected individuals in resource-limited settings of Southwest Ethiopia: a comparative cross-sectional study.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVancomycin-resistant enterococci (VRE) constitute a major global public health concern. These organisms can colonize the gastrointestinal (GI) tract for prolonged periods, ranging from months to years, and efforts to eradicate colonization are often only temporarily effective, with recurrence occurring within days or weeks. In immunocompromised individuals, particularly people living with HIV, VRE colonization may progress to clinically significant infection. Therefore, this study aimed to determine the prevalence of VRE colonization and identify associated risk factors among HIV-positive patients attending Mettu Karl Comprehensive Specialized Hospital.
methodsA comparative cross-sectional study was conducted from July to September 2023 among 308 participants. Socio-demographic and clinical data were collected using a pretested structured questionnaire and a standardized checklist. Stool samples were collected for the isolation and identification of Enterococci using standard microbiological methods. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion technique. Data were entered into Epi Data version 3.1 and analyzed using SPSS version 26. Bivariable and multivariable logistic regression analyses were employed to assess the association between presumptive VRE colonization and potential risk factors. Variables with adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were used to determine the strength of associations, and a p-value of ≤ 0.05 was considered statistically significant.
resultsEnterococci were found in 56.8% (175 out of 308) of participants, with 9.1% (16 of 175) identified as presumptive VRE. Among HIV-positive individuals, the presumptive VRE colonization rate was 11.2% (11 cases), compared to 6.5% (5 cases) in HIV-negative individuals. Overall, 46.9% of the enterococci isolates showed multidrug resistance (MDR).Being hospitalized within the past six months was significantly associated with presumptive VRE colonization: (AOR = 0.148; 95% CI: 0.031-0.707; p = 0.017).
conclusionPresumptive VRE colonization rates were 11.2% among HIV-positive individuals and 6.5% among HIV-negative individuals; however, this difference was not statistically significant. Recent hospitalization were significant risk factors. Therefore, stronger antibiotic stewardship and infection control practices are recommended for people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.